



Novel Insight in the Etiology of CRC: Genetics, Diagnosis, Management and Risk Assessment

Guest Editors:

Dr. Mev Dominguez Valentin

Department of Tumor Biology,
The Norwegian Radium Hospital,
Part of Oslo University Hospital,
Oslo, Norway

Dr. Pål Moller

Department of Tumor Biology,
The Norwegian Radium Hospital,
Part of Oslo University Hospital,
Oslo, Norway

Deadline for manuscript
submissions:

closed (20 February 2023)

Message from the Guest Editors

Early onset CRC (EOCRC) is reported to have increasing incidence, and as many as ~18% of patients diagnosed with CRC < age of 50 years (EOCRC) have pathogenic germline variants in genes that are not traditionally associated with CRC, including ATM, CHEK2, BRCA1, BRCA2, CDKN2A and PALB2 genes. The causes for familial clustering of CRC in older ages are less clear. An increase in CRC incidence should be caused by environmental factors, including interaction between genetic and environmental causative factors. Comprehensive testing for multiple genes, both in families and in incident cases, is now generating new knowledge for these topics. Early detection of and screening for cancer may cause overdiagnosis. In addition to treatment of cancer, health care includes knowledge and public education on lifestyle, clean environment, and the inherited cancer syndromes' medical genetic services. This should cover both high- and low-income areas. The current issue aims to increase knowledge for such aims.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)